Log in

LON:DPHDechra Pharmaceuticals Share Price, Forecast & News

GBX 2,890
-12.00 (-0.41 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
2,890
Now: GBX 2,890
2,950
50-Day Range
2,622
MA: GBX 2,801.88
2,926
52-Week Range
388
Now: GBX 2,890
3,090
Volume150,447 shs
Average Volume282,452 shs
Market Capitalization£3.12 billion
P/E Ratio103.96
Dividend Yield1.12%
BetaN/A
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians worldwide. It operates through European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development segments. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and locomotion and pain management products for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for dogs and cats under the Specific brand; distributes veterinary pharmaceuticals and equipment; and offers financial services. The company markets its products through wholesaler and distributor networks. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.
Read More
Dechra Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.1Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.29 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1606-814730

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£498.90 million
Cash FlowGBX 62.44 per share
Book ValueGBX 464.10 per share

Profitability

Miscellaneous

Employees1,437
Market Cap£3.12 billion
Next Earnings Date9/7/2020 (Estimated)
OptionableNot Optionable

Receive DPH News and Ratings via Email

Sign-up to receive the latest news and ratings for DPH and its competitors with MarketBeat's FREE daily newsletter.

Dechra Pharmaceuticals (LON:DPH) Frequently Asked Questions

How has Dechra Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Dechra Pharmaceuticals' stock was trading at GBX 2,472 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, DPH stock has increased by 16.9% and is now trading at GBX 2,890. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Dechra Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dechra Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Dechra Pharmaceuticals.

When is Dechra Pharmaceuticals' next earnings date?

Dechra Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, September 7th 2020. View our earnings forecast for Dechra Pharmaceuticals.

How often does Dechra Pharmaceuticals pay dividends? What is the dividend yield for Dechra Pharmaceuticals?

Dechra Pharmaceuticals declared a dividend on Monday, February 24th. Stockholders of record on Thursday, March 5th will be paid a dividend of GBX 10.29 per share on Wednesday, April 8th. This represents a dividend yield of 0.37%. The ex-dividend date of this dividend is Thursday, March 5th. The official announcement can be seen at this link. View Dechra Pharmaceuticals' dividend history.

What price target have analysts set for DPH?

4 brokerages have issued twelve-month price objectives for Dechra Pharmaceuticals' stock. Their forecasts range from GBX 2,510 to GBX 3,200. On average, they expect Dechra Pharmaceuticals' share price to reach GBX 2,931.25 in the next twelve months. This suggests a possible upside of 1.4% from the stock's current price. View analysts' price targets for Dechra Pharmaceuticals.

Has Dechra Pharmaceuticals been receiving favorable news coverage?

Media stories about DPH stock have been trending negative this week, InfoTrie reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Dechra Pharmaceuticals earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the next few days. View the latest news about Dechra Pharmaceuticals.

Who are some of Dechra Pharmaceuticals' key competitors?

What other stocks do shareholders of Dechra Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dechra Pharmaceuticals investors own include 32Red (TTR), Supergroup (SGP), JD Sports Fashion (JD), Ashtead Group (AHT), Cranswick (CWK), Drax Group (DRX), RPC Group (RPC), Robert Walters (RWA), SkyePharma (SKP) and Barratt Developments (BDEV).

Who are Dechra Pharmaceuticals' key executives?

Dechra Pharmaceuticals' management team includes the following people:
  • Mr. Ian D. Page, CEO, MD & Exec. Director (Age 58)
  • Mr. Richard John Cotton, CFO & Director (Age 58)
  • Dr. Anthony Gerard Griffin, MD of Dechra Veterinary Products for Europe & Exec. Director (Age 56)
  • Ms. Katy Clough, Group HR Director
  • Mr. Mike Eldred, Pres of North America (Age 49)

What is Dechra Pharmaceuticals' stock symbol?

Dechra Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "DPH."

How do I buy shares of Dechra Pharmaceuticals?

Shares of DPH and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Dechra Pharmaceuticals' stock price today?

One share of DPH stock can currently be purchased for approximately GBX 2,890.

How big of a company is Dechra Pharmaceuticals?

Dechra Pharmaceuticals has a market capitalization of £3.12 billion and generates £498.90 million in revenue each year. Dechra Pharmaceuticals employs 1,437 workers across the globe.

What is Dechra Pharmaceuticals' official website?

The official website for Dechra Pharmaceuticals is www.dechra.com.

How can I contact Dechra Pharmaceuticals?

Dechra Pharmaceuticals' mailing address is 24 Cheshire Business Park Cheshire Avenue, NORTHWICH, CW9 7UA, United Kingdom. The company can be reached via phone at +44-1606-814730.

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.